he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看离散地址
上一页:脑瘤患儿死亡简析
下一页:女性癫痫,这些问题你有非议吗?
- 2022-05-04癫痫病的确诊因素主要有哪些
- 2022-04-26导致癫痫病的主要病症是什么
- 2022-04-212013年国际抗癫痫联会抗癫痫药使用指南
- 注意┃要好好照顾,不仅可以避免妇科疾病,还有助于怀孕!
- Eur J Cancer:单纯前哨淋巴结切除术有望取代早期宫颈癌的盆腔淋巴结清洁!
- 治疗细菌性炎 6食谱防治效果好(2)
- 【预约直播】铿锵的论道 不炎,越来越多--「郁金香论坛」学术沙龙即将举行
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 2016AAN:神经专家发表了有前途的专业见解
- 害羞┃做女孩太难了!乳晕是粉色的好女孩?
- J Allergy Clin Immunol:IgE对鼻息肉有影响吗?
- 月经性癫痫患者妊娠期癫痫控制更好
- Medpage Today:不同类型的抗癫痫药物更有利
- 癫痫怎样治疗?xgrb
- 上海率先探索异地就医门诊费直接结算
- 癫痫猝死:凶手是谁?
- 小妹妹一股异味怎么了?
- BMJ:血浆置换对ANCA相关性血管炎患者的影响
- 治疗癫痫比较好的方法是什么?
- 有什么禁忌吗?
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 研究发现,置入支架接近手术打开动脉的再堵塞风险
- 非淋性尿道炎症状 非淋性尿道炎怎么办?
- 在泰国,女性子宫实际上需要这些试管婴儿手术
- 专注于小核酸药物的佑嘉生物完成A几千万元融资,渤溢基金领投,凯成资本担任首席财务顾问
- JCLA:坏死因子的功能性变体β颞下颌紊乱对基因的影响
- 黑芝麻的营养价值 吃黑芝麻的好处
- 北京妇产医院首都医科大学第九届妇科内镜技术手拉手培训班
- 2013国际抗癫痫联合会抗癫痫药用指南
- 羊角病能生孩子吗?
- 北京癫痫病手术款项
- 泡温泉时不应忽略的一定会
- 三庚酸亚胺或可治疗1型转运体缺陷综合征
- 关于癫痫治疗,患者和亲友最容易犯的错误
- 癫痫病发病确实是怎么回事
- 月经性病症患者孕期病症控制更佳
- 病例面对:20 岁男性,癫痫后记忆缺失
- 为啥狗狗睡觉时抽搐,是身体有问题还是在作梦,文章为你解答!
- 癫痫病治疗费用非常少多少钱
- 黑芝麻的营养价值 吃到黑芝麻的好处
- 惊厥性癫痫持续状态如何正确用药?近期共识告诉你
- 癫痫患者如何消除忘记吃药的毛病
- 癫痫病吃掉什么可以控制